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a b s t r a c t
The consistent and speciﬁc presence of Equus caballus papillomavirus type 2 (EcPV2) DNA and mRNA in
equine genital squamous cell carcinoma (gSCC) is suggestive of an etiological role in tumor development.
To further validate this concept, EcPV2-neutralizing serum antibody titers were determined by an
EcPV2 pseudovirion (PsV) neutralization assay. Furthermore, an EcPV2 L1 virus-like particle (VLP)-based
vaccine was generated and its prophylactic efﬁcacy evaluated in vivo.
All 6/6 gSCC-affected, but only 3/20 tumor-free age-matched animals revealed EcPV2-neutralizing
serum antibody titers by PsV assay. Vaccination of NZW rabbits and BalbC mice with EcPV2 L1 VLP using
Freund's or alum respectively as adjuvant induced high-titer neutralizing serum antibodies (1600–
12,800). Passive transfer with rabbit EcPV2–VLP immune sera completely protected mice from
experimental vaginal EcPV2 PsV infection.
These ﬁndings support the impact of EcPV2 in equine gSCC development and recommend EcPV2 L1
VLP as prophylactic vaccine against EcPV2 infection and associated disease in equids.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Papillomaviruses (PV) are a large group of epitheliotropic DNA
viruses that ubiquitously infect vertebrates, causing mostly benign
papillomas (warts), and rarely malignant intraepithelial neoplasia and
invasive cancer. More than 60 animal PV and 160 human PV (HPV)
genotypes have been completely characterized thus far (Bernard et al.,
2010). In humans, 15 to 20 oncogenic (high-risk) HPV types are
causally associated with development of squamous cell carcinomas
(SCC) of the anogenitalia – most notably the uterine cervix – and the
oropharynx, which together contribute 5% to the human cancer cases
worldwide (de Martel et al., 2012; Parkin, 2006; zur Hausen, 2009).
SCC represents the most common type of horse cancer (20% of all
equine malignant tumors), which can affect any body site, yet
predominate at sites with muco-cutaneous transition such as the
external genitalia (57%), the head and ocular region (43%)
(Knowles et al., 2015; Strafuss, 1976). Equine SCC usually emerges from
non-invasive precursor lesions including plaques, papillomas and
in situ carcinomas. There is growing evidence for Equus caballus
papillomavirus type 2 (EcPV2) being causally involved in the patho-
genesis of equine genital SCC (gSCC) and its precursor lesions (Knight
et al., 2011; Scase et al., 2010; Sykora et al., 2012). Viral DNA and tran-
scripts were consistently found in lesions, but not in normal adjacent
tissue or non-genital SCC (Scase et al., 2010), and only sporadically in
genital swabs or smegma of tumor-free horses (Bogaert et al., 2012;
Fischer et al., 2014; Sykora et al., 2012). In previous studies EcPV2 DNA
was detected in 45–90% of all penile SCC (Bogaert et al., 2012; Knight
et al., 2011). Little is known about the natural route of EcPV2
transmission, although anecdotal reports indicate that virus can be
transmitted via direct contact (Sykora et al., 2012). Moreover, the
assumed EcPV2 infection-related mechanisms underlying tumor
pathogenesis remain to be elucidated, and information on the ser-
oprevalence of EcPV2 in gSCC-affected horses is still lacking. Addressing
these issues is of importance, as similar pathological features, the
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presumed direct route of transmission, and external genitalia as
preferential sites of infection could establish EcPV2-positive gSCC as a
correlative naturally occurring PV-associated genital tumor.
For humans three multivalent HPV vaccines have been introduced
that target mucosal PV infections. These subunit vaccines comprise
virus-like particles (VLPs) self-assembled from the L1 major capsid
proteins of high-risk HPV16/18 (bivalent), HPV6/11/16/18 (quadriva-
lent), or HPV6/11/16/18/31/33/45/52/58 (nonvavalent) adsorbed to
adjuvant. VLPs are empty capsids that morphologically and immuno-
logically mimic authentic virions and induce high-titers of type-
restricted neutralizing antibodies. Animal vaccination trials with VLP-
based immunogens have been conducted with CRPV (cottontail rabbit
PV) in rabbits (Breitburd et al., 1995), COPV (canine oral PV) in dogs
(Suzich et al., 1995), BPV4 in cattle (Kirnbauer et al., 1996), and, more
recently, BPV1/2 in horses (Hainisch et al., 2012). A murine challenge
model based on vaginal infection with PV pseudovirions (PsV), i.e. PV
L1/L2 capsids harboring a reporter plasmid, mimics the natural
situation in vivo. Following infection of mucosal keratinocytes and
expression of the reporter protein (Luciferase), the latter can be
detected in vivo by bioluminescence imaging (Roberts et al., 2007).
This model has proven more sensitive in the detection of protective
antibodies induced by PV vaccines compared to in vitro PsV neutraliza-
tion assays (Longet et al., 2011).
In a serological pilot study, we have developed an EcPV2 neutra-
lization assay and evaluated the immune response of horses to natural
exposure with EcPV2. Furthermore, given the severity of equine gSCC
disease and current limitations of therapy, we have generated a
prophylactic EcPV2 L1 VLP vaccine and addressed its protective
efﬁcacy in a murine experimental EcPV2 PsV challenge model.
Results
EcPV2 seroprevalence in gSCC-affected and clinically tumor-free
horses
EcPV2 pseudovirions (PsV), i.e. viral capsids harboring the alkaline
phosphatase-expressing reporter plasmid pYSEAP, were generated as
virion surrogate for the development of an EcPV2 neutralization assay.
Codon-modiﬁed synthetic genes encoding EcPV2 L1 major and L2
minor capsid proteins (Scase et al., 2010) were synthesized and
transferred into 293TT cells, PsV were puriﬁed on Optiprep gradients
and a PsV-based neutralization assay (PBNA) was established accord-
ing to Buck et al. (2004). Using this assay, sera of six horses with
histologically conﬁrmed, EcPV2 DNA-positive gSCCs (Sykora et al.,
2012), and of 29 apparently tumor-free control horses were assessed
for the presence of EcPV2-neutralizing antibodies (Table 1).
PBNA revealed EcPV2-neutralizing antisera in 6/6 (100%) horses
diagnosed with penile or vulvar SCC conﬁrmedly harboring EcPV2
DNA, with titers ranging from 50 to 3200. From 20 age-matched
control animals, three (15%; #12, 14 and 21) were seropositive,
with titers ranging between 50 and 400. Interestingly, genital
swabs/smegma obtained from these three horses had also scored
positive for EcPV2 DNA. Furthermore, two of the three seropositive
control horses (#12 and #14) had been co-stabled for many years
with animals bearing gSCC (an Icelandic gelding not included in
this study and mare #6). No information on the stabling history
was available for #21. In contrast to EcPV1-induced juvenile
papillomas, gSCC mainly affect older animals (Junge et al., 1984)
thus it is noteworthy that the small number of younger horses
enrolled in this study (n¼9; medium age 3.8 years; maximum age
8 years) tested seronegative for EcPV2. This ﬁnding indicates that
either infection occurs later in life (by increasing cumulative
number of close or sexual contacts), or that seroconversion is rare
or short-lived in transiently infected animals but may increase
with persistent infection.
Generation of EcPV2 L1 virus-like particles (VLP)
To develop a prophylactic vaccine for preventing infection and
ensuing disease, EcPV2 L1 VLP was generated. The EcPV2 L1 ORF
was PCR ampliﬁed from DNA isolated from an equine penile
carcinoma, sub-cloned into baculovirus transfer vector pEVmod
(Kirnbauer et al., 1992), and veriﬁed by bidirectional sequencing.
Two clones were isolated, one harboring a wild-type (wt) L1
sequence (Scase et al., 2010), and one containing a mutated (mut)
form of L1. The latter comprised an unintentionally introduced
point mutation (A1110G) predicted to change the highly conserved
amino acid (aa) 370 Glutamic acid to Glycine (E370G). Two
recombinant baculoviruses were isolated and L1 proteins expressed
in Sf9 insect cells (Schellenbacher et al., 2009). SDS-PAGE and
Coomassie-staining of crude cell lysates and gradient-puriﬁed
protein preparations (Shafti-Keramat et al., 2003) revealed EcPV2
wt L1 VLP and mut L1 migrating as 50 KD proteins (Fig. 1A, n).
Negatively stained preparations were visualized by transmission
electron microscopy (TEM), demonstrating assembly into spherical
particles with the expected diameter of 50–55 nm for EcPV2 wt
L1, whereas EcPV2 mut L1 aggregated into irregular complexes
(Fig. 1B).
Immunization with EcPV2 wt L1 VLP and EcPV2 mut L1 protein
To analyze immunogenicity of EcPV2 wt L1 VLP in comparison to
non-assembled mut L1 protein, one New Zealand White (NZW) rabbit
each was immunized on days 0, 21 and 42 with 50 mg of the respective
protein using complete or incomplete Freund's adjuvant (CFA/IFA). In
addition, ﬁve Balb/C mice were subcutaneously immunized on days 0,
14 and 28 with 10 mg of EcPV2 wt L1 VLP using clinically relevant (less
reactogenic) aluminum hydroxide adjuvant. All sera were drawn two
weeks after the ﬁnal boost. Rabbit antisera were tested in serial log
dilutions (10–2 to 10–7) for L1-speciﬁc antibody responses by ELISA
(Fig. 2A), using either wt L1 VLP or mutated L1 protein as ELISA
antigens. Under native ELISA conditions, post-immune but not pre-
immune sera revealed antibody titers of 100,000 against L1 VLP, and of
1,000,000 against mut L1 protein. Similar titers were observed when
using denatured preparations of L1 VLP (10,000) or mut L1 protein
(1,000,000) as antigens (not shown).
Vaccination with EcPV2 wt L1 VLP, but not mut L1 protein, induced
high-titer neutralizing antisera in rabbits and mice
Neutralizing antisera raised to PV virions are directed to con-
formation-dependent epitopes present on assembled VLP (or
pentamer subunits) and correlate with vaccine efﬁcacy (Harro
et al., 2001). Therefore rabbit immune sera were tested in PBNA
using EcPV2 PsV consisting of assembled wt EcPV2 L1 and L2,
enclosing the reporter plasmid pYSEAP (Fig. 2B). Rabbit antiserum
to L1 VLP was neutralizing at high titers (6400), whereas anti-
serum to mut L1 protein or pre-immune serum did not neutralize
EcPV2 PsV at the highest concentration tested (dilution of 1:50).
Each of 5 mouse antisera against EcPV2 wt L1 VLP also neutralized
PsV with titers ranging between 1600 and 12,800 (Fig. 2B).
Passive transfer of neutralizing antiserum raised against VLP
protected mice against vaginal infection with EcPV2 PsV
To evaluate efﬁcacy of prophylactic vaccination with EcPV2 L1
VLP, we used a well-established murine genital challenge model with
EcPV2 PsV (Roberts et al., 2007). Mice were passively transferred (i.v.)
with 20 μl of rabbit pre-immune or immune serum to EcPV2 wt L1
VLP, EcPV2 mut L1 protein, or BPV1 L1 VLP and challenged with
luciferase-encoding EcPV2 PsV. Mice (5 per group) that had received
EcPV2 VLP immune serumwere completely protected against vaginal
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infection with EcPV2 PsV (Fig. 3A and B). In contrast, biolumines-
cence imaging detected genital EcPV2 PsV infection in mice trans-
ferred with antiserum raised against EcPV2 mut L1 protein,
heterologous BPV1 L1 VLP, or the respective pre-immune sera,
conﬁrming conformational dependence and type speciﬁcity of pro-
phylactic EcPV2 VLP vaccination (Fig. 3B).
Discussion
Knowledge about PV infections in horses and other equids, e.g.
donkeys, zebras and mules, had been limited to trans-species
infection by sarcoid-inducing BPV1 and 2, until EcPV1 could be
established as the causative agent of juvenile papillomas (Chambers
et al., 2003; Ghim et al., 2004; O'Banion et al., 1986). In recent years,
additional EcPV types 2 to 7 have been identiﬁed and substantial
evidence has accumulated for causal contribution of EcPV2 in the
development of equine gSCC (Bogaert et al., 2012; Kainzbauer et al.,
2012; Scase et al., 2010; Scott and Miller, 2003; Sykora et al., 2012).
The advanced age of horses bearing EcPV2-positive genital lesions
(Junge et al., 1984; Lange et al., 2013), the description of EcPV2-
positive gSCC and precursor lesions, and the occasional detection of
EcPV2 DNA from genital swabs (and most notably smegma) from
apparently healthy animals living in close contact with gSCC-
bearing horses (Sykora et al., 2012) are features shared by high-
risk HPV-induced genital disease. Although only a small number of
gSCC-affected horses (n¼6) were available for this pilot study, 100%
(6/6) of these animals tested seropositive to EcPV2 L1, as compared
to 15% (3/20) of age-matched, or 10.3% (3/29) of all apparently
tumor-free control horses enrolled in this study.
Although human cervical cancer correlates stronger with ser-
opositivity to the early viral oncoprotein E6 than to the viral capsid
proteins L1 and L2 (Kirnbauer et al., 1994; Viscidi et al., 1993), the
seroprevalence of HPV16 capsid antibodies in cervical cancer
patients was signiﬁcantly higher than in control groups (Kim
et al., 1999). Even if shown in a limited number of cases and
controls the strong association of EcPV2 L1 seropositivity (100%)
with equine genital lesions harboring EcPV2 DNA further strength-
ens the concept of a causal involvement of EcPV2 infection in the
development of equine gSCC and corresponding precursor lesions.
The clinical relevance of EcPV seropositivity in lesion-free
horses remains less well-deﬁned. A recent study from Switzerland
enrolling 50 clinically healthy horses reported 10% EcPV2 DNA
positivity without corresponding antibody titers, an even higher
EcPV2 seropositivity of 28% without DNA detection, and 8% of
animals positive for both EcPV2 DNA and antibodies (Fischer et al.,
2014). Seropositivity against EcPV2 L1 is a positive marker for past
or present productive EcPV2 infections and may therefore detect
possibly contagious animals, whereas the negative predictive
value of EcPV2 seronegativity is limited. In humans 40–60% of
women seroconvert following cervical HPV DNA detection and
antibody titers are signiﬁcantly lower than those raised by HPV
vaccination. Whether discordances are due to different stages of
infection were not clearly answered neither in humans nor equids.
Seropositivity was also observed for three tumor-free control
horses, i.e. one Warmblood mare, and two geldings of Icelandic
Table 1
Demographics and neutralizing antibody titers against EcPV2 pseudovirions (PsV) in horses bearing vulvar/penile SCC, and tumor-free horses.
Neutralizing antibody titers against ECPV-2 pseudovirions in horses by age and genital SCC
Vulvar/Penile SCC (n¼6) Tumor-free (n¼29)
N1 Sex Age (y) Neutralization titer N1 Sex Age (y) Neutralization titer
#1 m 24 3200 #7 m 30 0
#2 f 24 3200 #8 f 30 0
#3 f 22 100 #9 m 24 0
#4 m 420* 400 #10 f 22 0
#5 f 420* 50 #11 m 21 0
#6 f 20 50 #12 m 20 200
EcPV2 Seropositivity 6/6 (100%) #13 m 20 0
(420 years) #14 f 20 50
#15 m 19 0
#16 m 19 0
#17 m 19 0
#18 f 19 0
#19 m 18 0
#20 m 18 0
#21 m 17 400
#22 m 17 0
#23 m 17 0
#24 f 17 0
#25 f 16 0
#26 m 15 0
EcPV2 Seropositivity 3/20 (15%)
(Z15 years)
#27 f s 0
#28 m 7 0
#29 f 7 0
#30 m 4 0
#31 m 4 0
#32 m 1 0
#33 m 1 0
#34 f 1 0
#35 f 1 0
EcPV2 Seropositivity 0/9 (0%)
(r8 years)
Antisera of 29 healthy horses (n¼20 Z15 years; n¼9 r8 years), and 6 equids suffering from vulvar or penile SCC (Z20 years), were analyzed for neutralizing antibodies
against EcPV2 PsV using endpoint 2-fold serial dilutions (starting at 1:50 up to 1:25,600). Titers o50 are scored as 0.
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breed. The seropositive mare #14 had been co-stabled with the
SCC-bearing mare #6 for many years but remained free from
disease within a six-year observation period (2007–2012). Inter-
estingly, mare #14 tested negative for EcPV2 L1 neutralizing
antibodies six years later (2012) indicating transient infection.
Similarly, one of the EcPV2 L1-seropositive geldings (#12) had
lived for several years in close contact with an Icelandic horse
bearing an untreated EcPV2-positive penile SCC, before being
moved to another place. No history is available for the third
seropositive Icelandic gelding (#21). The two seropositive geldings
have been clinically examined for three years since blood collec-
tion and have since remained tumor-free.
Together with the fact that EcPV2-associated genital lesions are
predominantly encountered in older horses, these observations
indicate that EcPV2 infection is cleared in a subset of younger,
immunocompetent horses, whereas it may persist in other indi-
viduals and cause progressive lesions at advanced age. Genital
SCC-affected, EcPV2 L1-seropositive gelding #2 was imported from
Iceland before 1997 and developed a penile SCC after 2010.
Interestingly, sequencing of intralesional viral DNA revealed an
‘Iceland-speciﬁc’ EcPV2 variant (Kainzbauer et al., 2012; Scase
et al., 2010; Sykora et al., 2012); (unpublished data), indicating
that infection had occurred before 1997 and persisted before
tumor development, possibly by age-related changes in the
immune-status, and/or hormone, cytokine and/or growth factor
levels, as proposed by Maglennon and Doorbar (2012).
Seropositivity may identify potentially contagious horses with
productive benign lesions or disease preceding tumor development.
Before introduction of valuable animals into stables with cases of gSCC
or with a signiﬁcant percentage of seropositive animals, susceptible
horses may beneﬁt from prophylactic EcPV2 vaccination.
In agreement with previously reported EcPV2 DNA detection rates
for clinically healthy horses (0–10%) (Bogaert et al., 2012; Sykora
et al., 2012), a recent study from Switzerland reported 10% EcPV2 DNA
positivity for genital samples, and EcPV2 L1-speciﬁc seropositivity for
28% of 50 healthy animals tested (Fischer et al., 2014). This higher
EcPV2 seroprevalence obtained by ELISA when compared to 15%
seropositivity determined by the herein described PBNA possibly
reﬂects the pronouncedly higher speciﬁcity of the latter method
(Pastrana et al., 2004). As observed for L1-VLP ELISA, it is reasonable
to assume that non-assembled L1-GST ELISA results in higher overall
but less speciﬁc L1 detection rates when compared to the more
stringent PBNA, which speciﬁcally detects neutralizing antibodies. The
EcPV2 PBNA herein thus represents a more stringent method for
analysis of protective serum antibodies following natural infection
(Zhao et al., 2014), and for seroepidemiological studies on the
prevalence of EcPV2 and age distribution in different equid popula-
tions. Such studies would also guide informed decisions on the ideal
age for future EcPV2 vaccinations in equid stocks.
As demonstrated for the L1 proteins of many other PV types
including EcPV1 (Ghim et al., 2004), recombinantly expressed EcPV2
wt L1 protein efﬁciently assembled into VLP. Assembly was disrupted
by a single aa point mutation (E370G) targeting a highly conserved
motif in the beta1 sheet structure of L1, as identiﬁed in small T¼1
HPV16 L1 capsids (Bishop et al., 2007; Kirnbauer et al., 1993).
Immunization with EcPV2 wt L1 VLP (and mut L1 protein) induced
high-titers of antibodies against L1 epitopes when assessed by ELISA
using wt L1 VLP or mut L1 protein as antigen in native or denatured
form, suggesting that a signiﬁcant proportion of antibodies induced by
L1 VLP (and mut L1) recognizes linear epitopes. In contrast, neutraliz-
ing antibodies were only generated against conformational epitopes of
the assembled immunogenic wt L1 VLP capsid, supporting the
importance of the native structure of the L1 immunogen for induction
of protective antibody responses (Kirnbauer et al., 1992).
The establishment of a murine cervico-vaginal challenge model
(Roberts et al., 2007) has facilitated investigations of the mechan-
isms of genital PV infection and of vaccine efﬁcacy in vivo. EcPV2
PsV enclosing a luciferase reporter gene efﬁciently infected the
genital murine mucosa, comparable to mucosal high-risk HPVs
(Schellenbacher et al., 2013). As expected, passive transfer of EcPV2
wt L1 VLP antiserum completely protected mice from experimental
EcPV2 infection. Based on previous studies on HPV VLP vaccines,
Fig. 1. Recombinant wild-type EcPV2 L1 (A) but not mutated EcPV2 L1 (B) assembles into virus-like particles (VLP). Following PCR-cloning of EcPV2 L1 ORF into transfer vector
pEVmod, DNA sequencing identiﬁed both a wild-type (wt) and a mutated (mut) L1 clone (E370G). Following expression by recombinant baculoviruses in insect cells, protein
bands speciﬁc for the full length L1 protein migrated at 50 KD (indicated by n) by SDS-PAGE and Coomassie-staining following density gradient puriﬁcation for both wt and
mut L1. Transmission electron microscopy of negatively stained preparations revealed assembly into VLP for wt L1, and irregular aggregates for mut L1 protein (B).
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protection against PsV-infection in this model is a valuable surrogate
of prophylactic L1 VLP vaccine efﬁcacy in preventing persistent viral
infection and consequent disease (Jagu et al., 2009) as determined in
randomized controlled clinical trials (Day et al., 2012).
SCC and sarcoids are the two most common tumor types
diagnosed in equids (Knowles et al., 2015; Sundberg et al., 1977)
which pronouncedly impair the health, welfare and material value
of equids. If the causal role of EcPV2 infection in penile and vulvar
cancer development can be ﬁrmly proven, half to two thirds of horse
tumors, i.e. gSCC and sarcoids, could be prevented by a vaccine that
protects against infection by BPV1/2 and EcPV2. We have previously
demonstrated that BPV1 L1 VLPs efﬁciently protect horses from
experimental challenge with BPV1 virions (Hainisch et al., 2012;
Kirnbauer et al., 1996), and that anti-BPV1 L1 antibodies cross-
neutralize BPV2 (Shafti-Keramat et al., 2009). Herein, we show that
passive transfer of rabbit antiserum to EcPV2 L1 VLP efﬁciently
protects mice from EcPV2 PsV challenge. Consequently, similar to
licensed HPV vaccines, a bivalent BPV1/EcPV2 L1 VLP vaccine has the
potential to signiﬁcantly reduce the incidence of PV-associated
(semi-)malignant diseases in horses and other equids.
Material and methods
Animals
Tumor bearing (minimum age of 20 years as documented for
equids #1, #2, #3, #6, or estimated by owners for #4 and #5) and
control horses (age Z15 years, mean 19,9) were owned by, and
routinely treated at, the Equine Clinic at the Veterinary University
of Vienna. SCC were surgically removed, veriﬁed by routine
histopathology, serum samples obtained and stored at 20 1C.
Demographics: Information about age, sex and genital (penile or
vulvar) cancers is shown in Table 1.
EcPV2 pseudovirions (PsV)
Production of PsV and neutralization assays (PBNA) were per-
formed as described by Buck (http://home.ccr.cancer.gov/lco/protocols.
asp) with few minor modiﬁcations. EcPV2 PsV were generated by
codon modiﬁcation “as-different-as-possible” of NCBI reference
sequence NC_012123 (Scase et al., 2010). (http://home.ccr.cancer.gov/
lco/codonmodiﬁcation.htm). Altered L1 and L2 genes were synthe-
sized (Geneart-Invitrogen, Germany) and cloned into expression
vector pVITRO1-neo-mcs (Invivogen) using restriction enzyme sites
Bgl2 and Nhe1, or BamH1 and Avr2, respectively. The EcPV2 L1/L2
expression vector was co-transfected with reporter plasmid pYSEAP
(encoding for secreted-alkaline for in-vitro assays), or pCLucf (encod-
ing for ﬁreﬂy luciferase for in vivo infection of mice) into 293TT cells.
Recombinant EcPV2-L1 baculovirus expression vectors
EcPV-2 DNA was isolated from an equine penile SCC (Sykora et
al., 2012). To express recombinant EcPV2 L1 protein, the L1 ORF was
PCR ampliﬁed using a mixture of Taq and high-ﬁdelity polymerase
and primers complementary for EcPV2 sequence nucleotides (nt)
5673–5695, additionally introducing restriction enzyme (RE) site
BglII (50-CGATAGATCTACCTATAAATATGGCTTTCTGGACAATGAACA-
Fig. 2. Immunization with EcPV2 L1 VLP raises neutralizing antibodies in rabbits and mice. New Zealand White (NZW) rabbits were immunized (A) with 50 μg of EcPV2 wt
L1 VLP or mut L1 subcutaneously (week 0, 3, 6) using CFA/IFA adjuvant. BalbC (n¼5) were vaccinated (B) with 10 μg of EcPV2 wt L1 subcutaneously (week 0, 2, 4) using
aluminum hydroxide adjuvant. Antisera in indicated dilutions (10–2 to 10–7) were tested for L1-speciﬁc antibodies using EcPV2 wt L1 VLP and EcPV2 mut L1 protein in ELISA
(A). Immune sera of both rabbits and mice were analyzed for neutralizing antibodies (dilutions 1:50 to 1:25,600) in EcPV2 PsV-based neutralization assays (PBNA) (B). Titers
o50 are scored as 0.
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30), and (nt) 7174–7153 plus EcoRI RE site (50-CCTGGAATTCGCT-
TATGCCTTCCTTTTCTTGG-30). Subsequently, the amplimer was
cloned into the baculovirus transfer vector pEVmod (Kirnbauer
et al., 1992) and veriﬁed by RE digest and bidirectional sequencing
(VBC-Biotech, Vienna, Austria). Two clones were identiﬁed contain-
ing either wt or mut L1 (a single nt point mutation (A1110G)
changing a codon for highly conserved aa 370 Glutamic Acid (E) to
Glycine (G)). Recombinant baculoviruses were generated by
cotransfection of Sf-9 insect cells with transfer vectors and linear-
ized baculovirus DNA (BaculoGold; BD Biosciences). Expression in
SF9 insect cells and puriﬁcation of VLP on sucrose and CsCl density
gradients were performed as described previously and puriﬁed VLP
were visualized by negative stain and TEM at 30,000 magniﬁca-
tion (Schellenbacher et al., 2009).
Immunization
Following extensive dialysis of EcPV2 L1 proteins against PBS
containing 0.5 M NaCl, 1 mM CaCl2, and 0.02% Tween 80, NZW
rabbits were immunized with 50 μg of either wt or mut L1 protein
in CFA followed by boosts at weeks 3 and 6 in IFA. Balb/C mice
were immunized with 10 mg of wt L1-VLP at weeks 0, 2, and
4 using aluminum hydroxide as adjuvant (Alhydrogel 2%, Invivo-
gen, San Diego, CA). Blood samples were obtained 2 weeks after
the third immunization and sera stored at 20 1C. NZW rabbits
were immunized at Charles River Laboratories, Germany. Murine
studies have been approved (BMWF-66.009/0173–1I/3b/2011) and
animal care was in accordance to the guidelines of the Austrian
Federal Ministry for Science and Research.
EcPV2 enzyme-linked immunosorbent assay (ELISA)
Polyclonal antisera raised against EcPV2 L1-VLP (wt), or L1 protein
(mut), were tested for antibodies against both EcPV2 L1-VLP (wt) and
L1 protein (mut). Native proteins diluted in PBS (150 ng/100 ml PBS/1%
Non Fat Dry Milk) were coated onto 96-well microtiter plates (Nunc
MaxiSorp) overnight at 4 1C. Additionally, proteins were plated under
denaturing conditions (NaHCO3 pH 10.6, 0.01M DTT) overnight at
37 1C. After blocking with PBS/1% milk for 30 min, the antigen was
incubated with rabbit antisera serially diluted 10–2 to 10–7 in PBS/1%
milk for 1 h at room temperature. Finally a 1:5000 dilution of
peroxidase-conjugated goat anti rabbit-Ab (Bio-Rad) was added and
the plate was developed by adding the substrate ABTS (Bohringer
Mannheim). The optical density (OD) at 405 nmwas determined using
an ELISA reader (Dynatech).
EcPV2 pseudovirion based neutralization assay (PBNA)
Expression vectors for EcPV2 codon-modiﬁed L1 and L2 ORFs
were co-transfected with reporter plasmid pYSEAP or pCLucF.
Neutralization assays were performed according to an adapted
protocol (http://home.ccr.cancer.gov/lco/neutralizationassay.htm).
PsV were pre-incubated with 2-fold serial dilutions of horse sera
or EcPV2-L1 vaccinated rabbits or mice from 1:50 up to 1:25,600.
EcPV2 murine vaginal challenge
The intravaginal PsV challenge model (Roberts et al., 2007) was
adapted using microtrauma induced by a cytobrush to prime
vaginal mucosa for infection (Karanam et al., 2010). Twenty-ﬁve
female Balb/C mice in groups of ﬁve animals were pretreated with
subcutaneous injection of progesterone (3 mg Depo-Provera) four
days prior to vaginal challenge. Three days later mice were
passively transferred with 20 ml of rabbit serum: 1, EcPV2 L1 wt
preimmune 2, EcPV2 L1 mut preimmune 3, EcPV2 L1 wt immune
4, EcPV2 L1 mut immune 5, BPV1 L1 immune. 24 h later mice were
intraperitoneally anaesthetized with Ketamine/Xylazine, and a
mechanical microtrauma of the vaginal epithelium was set by
30 rotating a cervical cytobrush. Luciferase-encoding EcPV2 PsV
in 3% carboxymethylcellulose (CMC) (1:1) were inserted into the
Fig. 3. Passive transfer with EcPV2 L1 VLP antiserum completely protects mice from experimental vaginal challenge with EcPV2 PsV. Groups of mice (n¼5) were passively
transferred with 20 μl of pre-immune or immune sera to EcPV2 wt L1 VLP, mut L1 protein, or BPV1 L1 VLP into the tail vein and challenged with EcPV2 PsV encapsidating
Luciferase reporter plasmid. Three days later, PSV infection was determined by detection of Luciferase activity by bioluminescence imaging (Y-axis: average radiance; p/s/
cm2/sr), with the respective background luminescence (unvaccinated mice challenged with CMC only) subtracted from all data points.
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vaginal vault, and 72 h later infection was analyzed by detection of
luciferase-induced bioluminescence produced in the vagina upon
intravaginal application of 20 ml luciferin (Caliper; 7 mg/ml) into
anaesthetized animals. Bioluminescence was imaged in the vaginal
area (IVIS 50, Caliper). An identical region of interest (ROI) was
selected for all animals and luminescence data are given minus the
matching background signal (mice challenged with CMC only).
Statistical analysis was performed using the Microsoft Excel Soft-
ware and a two-tailed unpaired t-test (heteroscedastic) used to
calculate p-values.
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